Research
Hormonal
Tirzepatide significantly decreased food intake and reduced overall appetite scores.
Tirzepatide may help reduce appetite, aiding in weight loss efforts.
StrongSupportsmedium confidence
Tirzepatide also significantly decreased food intake, reduced overall appetite scores and increased fasting visual analog scale scores for satiety and fullness across different clinical trials.
Why this rating
The claim is supported by data from various clinical trials.
Source
The promise of tirzepatide: A narrative review of metabolic benefits
Sara Sokary et al. · Primary care diabetes · 2025
DOI 10.1016/j.pcd.2025.03.008
reviewCited 24×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide administration for 72 weeks elicited significant weight reduction ranging from 5% to 20.9% across different trials in a dose-dependent manner.Strong
- Tirzepatide exhibited favorable effects on glycemic control, with reductions in HbA1c levels ranging from 20.4 mmol/mol with the 5 mg dose to 28.2 mmol/mol with the 15 mg dose.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →